|
Clonal concordance and genomic heterogeneity in single CTC copy number alterations vs. paired IMPACT metastatic tissue sequencing from mCRPC patient samples. |
| |
|
Leadership - Asterias Biotherapeutics |
Consulting or Advisory Role - Clovis Oncology; Ferring; Janssen Research & Development; Onclive; Physicans' Education Resource; Sanofi; WIRB-Copernicus Group |
Research Funding - Illumina (Inst); Innocrin Pharma (Inst); Janssen (Inst) |
Travel, Accommodations, Expenses - Asterias Biotherapeutics; Onclive; Physicans' Education Resource; Sanofi; WIRB-Copernicus Group |
| |
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
| |
|
No Relationships to Disclose |
| |
|
Employment - Epic Sciences |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
| |
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
| |
|
|
Consulting or Advisory Role - Loxo; Pfizer |
| |
|
Research Funding - Illumina |
| |
|
No Relationships to Disclose |
| |
|
Employment - Epic Sciences |
Leadership - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
Patents, Royalties, Other Intellectual Property - Patents Pending |